107504-07-4

Basic information

• Product Name: 2-Pyridinecarboxylicacid,5-fluoro-,methylester(9CI)
• Synonyms: 2-Pyridinecarboxylicacid,5-fluoro-,methylester(9CI);5-Fluoropyridine-2-carboxylic acid methyl ester;Methyl 5-fluoropicolinate;Methyl 5-fluoropyridine-2-carboxylate;2-PYRIDINECARBOXYLIC ACID, 5-FLUORO-, METHYL ESTER;5-fluoro-2-pyridinecarboxylic acid methyl ester
• CAS NO: 107504-07-4
• Molecular Formula: C₇H₆FNO₂
• Molecular Weight: 155.13
• Product Categories: HALIDE
• Mol File: 107504-07-4.mol

Chemical Properties

• Boiling Point: 217.2°C at 760 mmHg
• Flash Point: 85.1°C
• Appearance: /
• Density: 1.243g/cm³
• Vapor Pressure: 0.135mmHg at 25°C
• Refractive Index: 1.49
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: -0.73±0.10(Predicted)
• CAS DataBase Reference: 2-Pyridinecarboxylicacid,5-fluoro-,methylester(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Pyridinecarboxylicacid,5-fluoro-,methylester(9CI)(107504-07-4)
• EPA Substance Registry System: 2-Pyridinecarboxylicacid,5-fluoro-,methylester(9CI)(107504-07-4)

Safety Data

• Hazardous Substances Data: 107504-07-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-Pyridinecarboxylic acid, 5-fluoro-, methyl ester (9CI) is used as a pharmaceutical intermediate for the synthesis of various drugs and drug candidates. Its unique structure and potential biological activity make it a valuable compound in the development of new therapeutic agents.
Used in Agrochemical Industry:
In the agrochemical industry, 2-Pyridinecarboxylic acid, 5-fluoro-, methyl ester (9CI) may be utilized as a precursor for the synthesis of agrochemicals, such as pesticides and herbicides. Its heterocyclic nature and potential biological activity could contribute to the development of effective and targeted agrochemical products.
Used in Research and Development:
2-Pyridinecarboxylic acid, 5-fluoro-, methyl ester (9CI) is used as a research compound in various scientific studies and experiments. Its unique properties and potential applications make it an interesting subject for exploration in the fields of chemistry, biology, and materials science. Researchers may investigate its interactions with biological systems, its potential as a therapeutic agent, or its use in the development of new materials and technologies.

InChI:InChI=1/C7H6FNO2/c1-11-7(10)6-3-2-5(8)4-9-6/h2-4H,1H3

Upstream product

• 107504-08-5 5-fluoropicolinic acid 
• 67-56-1 methanol 
• 29682-15-3 methyl 5-bromopicolinate 
• 29682-14-2 5-nitro-pyridine-2-carboxylic acid methyl ester 
• 67515-76-8 methyl 5-amino-2-pyridinecarboxylate 
• 132308-19-1 methyl 5-chloropyridine-2-carboxylate 

Downstream Products

• 31181-88-1 5-fluoropicolinaldehyde 
• 802325-29-7 5-fluoro-2-hydroxylmethylpyridine 
• 860296-24-8 6-chloro-5-fluoro-pyridine-2-carboxylic acid 
• 1214337-05-9 6-chloro-5-fluoro-2-picolinic acid methyl ester 

Relevant articles and documents

ASK1 inhibitor and application thereof

The invention relates to compounds represented by a general formula (I) shown in the specification, a pharmaceutically acceptable salt and ester, or a stereoisomer of the compounds. The invention alsorelates to a preparation method of the compounds, a pharmaceutical preparation and a pharmaceutical composition containing the compounds. The compounds provided by the invention can effectively inhibit the amino acid phosphorylation of ASK1 and inhibit the activation of the ASK1; therefore, the compounds can treat and/or prevent ASK1-mediated diseases and related diseases.

NOVEL OXALYL PIPERAZINES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV)

The present invention relates generally to novel antiviral agents. Specifically, the present invention relates to compounds which can inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV replication cycle, compositions comprising such compounds, methods for inhibiting HBV viral replication, methods for treating or preventing HBV infection, and processes and intermediates for making the compounds.

NOVEL INDOLIZINE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV)

The present invention relates generally to novel antiviral agents. Specifically, the present invention relates to compounds which can inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV replication cycle, compositions comprising such compounds, methods for inhibiting HBV viral replication, methods for treating or preventing HBV infection, and processes and intermediates for making the compounds.

Neurotrophic factor tyrosine kinase receptor inhibitor

The invention provides a neurotrophic factor tyrosine kinase receptor inhibitor. The tyrosine kinase receptor inhibitor provided by the invention has a tricyclic parent core structure, can inhibit theactivity of Trk kinase and can be used for treating mammalian diseases mediated by the Trk kinase.

PROCESS FOR FLUORINATING COMPOUNDS

Methods of preparing a fluorinated aryl or heteroaryl substrate by combining a quaternary ammonium cyanide and an aryl or heteroaryl substrate substituted with at least one chloro, bromo, sulfonyl, or nitro group to thereby provide a mixture, and combining the mixture with hexafluorobenzene to thereby provide the fluorinated substrate.

Mild fluorination of chloropyridines with in situ generated anhydrous tetrabutylammonium fluoride

This paper describes the fluorination of nitrogen heterocycles using anhydrous NBu4F. Quinoline derivatives as well as a number of 3- and 5-substituted pyridines undergo high-yielding fluorination at room temperature using this reagent. These results with anhydrous NBu4F compare favorably to traditional halex fluorinations using alkali metal fluorides, which generally require temperatures of ≥100 °C.

Pd-catalyzed nucleophilic fluorination of aryl bromides

On the basis of mechanism-driven reaction design, a Pd-catalyzed nucleophilic fluorination of aryl bromides and iodides has been developed. The method exhibits a broad substrate scope, especially with respect to nitrogen-containing heteroaryl bromides, and proceeds with minimal formation of the corresponding reduction products. A facilitated ligand modification process was shown to be critical to the success of the reaction.

NOVEL COMPOUNDS

This invention relates to compounds of formula (I) their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, Ar, R1, R2, R3 have meanings given in the description.

NOVEL COMPOUNDS

This invention relates to compounds of formula I their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, Ar, R1, R2, R3 have meanings given in the description.

FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES

The present invention relates to a compound of formula (I): (I); or a pharmaceutically acceptable salt or solvate thereof, wherein: Ring A is (4-12)-membered heterocyclyl; Ring B is a fused benzene ring selected from the group consisting of: B(i); and B(i